Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance

NCT ID: NCT03743610

Last Updated: 2024-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2023-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators expect to find that different intensity and altitude exposure levels will show what kind of intermittent exposure protocol is more beneficial to athletes and healthy individuals that experience acute exposure to altitude during exercise. This may furthermore be related to acute altitude exposure for recreational exercise use as well.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Altitude Hypoxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Effect of heart rate training in simulated altitude

Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining \>65% max heart rate during room air based maximal peak work.

Group Type EXPERIMENTAL

Simulated altitude

Intervention Type OTHER

Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines

Effect of saturation of oxygen training in simulated altitude

Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.

Group Type EXPERIMENTAL

Simulated altitude

Intervention Type OTHER

Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines

Effect of optimized training in simulated altitude

Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.

Group Type ACTIVE_COMPARATOR

Simulated altitude

Intervention Type OTHER

Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines

Effect of placebo training in non-simulated altitude

Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.

Group Type PLACEBO_COMPARATOR

Placebo simulated altitude

Intervention Type OTHER

Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simulated altitude

Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines

Intervention Type OTHER

Placebo simulated altitude

Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-70 years of age,
* history of good health,
* generally active to competitive athletes.

Exclusion Criteria

* History of cardiac or pulmonary disease,
* not currently active,
* unable to exercise or meet study requirements (e.g., number of sessions),
* live at altitude (\>2,100m or 7,000ft).
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Courtney M. Wheatley

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Courtney M Wheatley

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-000484

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hyperbaric VO2max Study
NCT02356900 TERMINATED PHASE2